REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $699,084 | -87.9% | 7,689 | -87.0% | 0.12% | -79.3% |
| Q3 2020 | $5,761,000 | -55.0% | 59,139 | -27.9% | 0.57% | -53.0% |
| Q2 2020 | $12,801,000 | +152.0% | 82,049 | +29.7% | 1.20% | +53.4% |
| Q3 2019 | $5,080,000 | -52.3% | 63,269 | -43.9% | 0.78% | -46.1% |
| Q2 2019 | $10,640,000 | +52.2% | 112,769 | +37.9% | 1.46% | +128.2% |
| Q1 2019 | $6,989,000 | -43.7% | 81,769 | -63.0% | 0.64% | -54.4% |
| Q4 2018 | $12,413,000 | +63.7% | 221,269 | +138.6% | 1.40% | +60.8% |
| Q3 2018 | $7,581,000 | +59.4% | 92,719 | -31.8% | 0.87% | +32.6% |
| Q2 2018 | $4,757,000 | +3.1% | 136,044 | -39.5% | 0.66% | -6.4% |
| Q1 2018 | $4,615,000 | -27.6% | 225,000 | 0.0% | 0.70% | -6.3% |
| Q4 2017 | $6,372,000 | -0.1% | 225,000 | +9.8% | 0.75% | -17.8% |
| Q3 2017 | $6,376,000 | – | 205,000 | – | 0.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |